Cargando…

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank

BACKGROUND & AIMS: Development of resistance results from mutations in the viral genome, and the presence of selective drug pressure leads to the emergence of a resistant virus population. The aim of this study was to analyze the impact of genetic variability on the genetic barrier to drug resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kliemann, Dimas Alexandre, Tovo, Cristiane Valle, Gorini da Veiga, Ana Beatriz, Machado, André Luiz, West, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978475/
https://www.ncbi.nlm.nih.gov/pubmed/27504952
http://dx.doi.org/10.1371/journal.pone.0159924
_version_ 1782447179503239168
author Kliemann, Dimas Alexandre
Tovo, Cristiane Valle
Gorini da Veiga, Ana Beatriz
Machado, André Luiz
West, John
author_facet Kliemann, Dimas Alexandre
Tovo, Cristiane Valle
Gorini da Veiga, Ana Beatriz
Machado, André Luiz
West, John
author_sort Kliemann, Dimas Alexandre
collection PubMed
description BACKGROUND & AIMS: Development of resistance results from mutations in the viral genome, and the presence of selective drug pressure leads to the emergence of a resistant virus population. The aim of this study was to analyze the impact of genetic variability on the genetic barrier to drug resistance to DAAs. METHODS: The genetic barrier was quantified based on the number and type of nucleotide mutations required to impart resistance, considering full-length HCV NS3, NS5A and NS5B regions segregated by genotype into subtypes 1a, 1b, 2a, 2b and 3a. This study analyzeds 789 NS3 sequences, 708 sequences and 536 NS5B sequences deposited in the European Hepatitis C Virus Database, in the following resistance-associated positions: NS3: F43/I/L/S/V, Q80K/R, R155K/G, A156G/S/T and D168A/C/E/G/H/N/T/V/Y; NS5A: L/M28A/T/V, Q30E/H/R, L31F/I/M/V, H58D or P58S and Y93C/F/H/N/S; NS5B: S282P/R/T, C316H/N/Y, S368T, Y448C/H, S556G/R, D559R. RESULTS: Variants that require only one transversion in NS3 were found in 4 positions and include F43S, R80K, R155K/G and A156T. The genetic barrier to resistance shows subtypic differences at position 155 of the NS3 gene where a single transition is necessary in subtype 1a. In the NS5A gene, 5 positions where only one nucleotide change can confer resistance were found, such as L31M which requires one transversion in all subtypes, except in 0.28% of 1b sequences; and R30H, generated by a single transition, which was found in 10.25% of the sequences of genotype 1b. Other subtypic differences were observed at position 58, where resistance is less likely in genotype 1a because a transversion is required to create the variant 58S. For the NS5B inhibitors, the genetic barrier at positions conferring resistance was nearly identical in subtypes 1a and 1b, and single transitions or transversions were necessary in 5 positions to generate a drug-resistant variant of HCV. The positions C316Y and S556D required only one transition in all genotypes, Y448H and S556 G/N/R positions required only one transition for up to 98.8% of the sequences analyzed. A single variant in position 448 in genotype 1a is less likely to become the resistance variant 448H because it requires two transversions. Also, in the position 559D a transversion and a transition were necessary to generate the resistance mutant D559H. CONCLUSION: Results revealed that in 14 out of 16 positions, conversion to a drug-resistant variant of HCV required only one single nucleotide substitutions threatening direct acting antivirals from all three classes.
format Online
Article
Text
id pubmed-4978475
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49784752016-08-25 Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank Kliemann, Dimas Alexandre Tovo, Cristiane Valle Gorini da Veiga, Ana Beatriz Machado, André Luiz West, John PLoS One Research Article BACKGROUND & AIMS: Development of resistance results from mutations in the viral genome, and the presence of selective drug pressure leads to the emergence of a resistant virus population. The aim of this study was to analyze the impact of genetic variability on the genetic barrier to drug resistance to DAAs. METHODS: The genetic barrier was quantified based on the number and type of nucleotide mutations required to impart resistance, considering full-length HCV NS3, NS5A and NS5B regions segregated by genotype into subtypes 1a, 1b, 2a, 2b and 3a. This study analyzeds 789 NS3 sequences, 708 sequences and 536 NS5B sequences deposited in the European Hepatitis C Virus Database, in the following resistance-associated positions: NS3: F43/I/L/S/V, Q80K/R, R155K/G, A156G/S/T and D168A/C/E/G/H/N/T/V/Y; NS5A: L/M28A/T/V, Q30E/H/R, L31F/I/M/V, H58D or P58S and Y93C/F/H/N/S; NS5B: S282P/R/T, C316H/N/Y, S368T, Y448C/H, S556G/R, D559R. RESULTS: Variants that require only one transversion in NS3 were found in 4 positions and include F43S, R80K, R155K/G and A156T. The genetic barrier to resistance shows subtypic differences at position 155 of the NS3 gene where a single transition is necessary in subtype 1a. In the NS5A gene, 5 positions where only one nucleotide change can confer resistance were found, such as L31M which requires one transversion in all subtypes, except in 0.28% of 1b sequences; and R30H, generated by a single transition, which was found in 10.25% of the sequences of genotype 1b. Other subtypic differences were observed at position 58, where resistance is less likely in genotype 1a because a transversion is required to create the variant 58S. For the NS5B inhibitors, the genetic barrier at positions conferring resistance was nearly identical in subtypes 1a and 1b, and single transitions or transversions were necessary in 5 positions to generate a drug-resistant variant of HCV. The positions C316Y and S556D required only one transition in all genotypes, Y448H and S556 G/N/R positions required only one transition for up to 98.8% of the sequences analyzed. A single variant in position 448 in genotype 1a is less likely to become the resistance variant 448H because it requires two transversions. Also, in the position 559D a transversion and a transition were necessary to generate the resistance mutant D559H. CONCLUSION: Results revealed that in 14 out of 16 positions, conversion to a drug-resistant variant of HCV required only one single nucleotide substitutions threatening direct acting antivirals from all three classes. Public Library of Science 2016-08-09 /pmc/articles/PMC4978475/ /pubmed/27504952 http://dx.doi.org/10.1371/journal.pone.0159924 Text en © 2016 Kliemann et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kliemann, Dimas Alexandre
Tovo, Cristiane Valle
Gorini da Veiga, Ana Beatriz
Machado, André Luiz
West, John
Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
title Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
title_full Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
title_fullStr Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
title_full_unstemmed Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
title_short Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
title_sort genetic barrier to direct acting antivirals in hcv sequences deposited in the european databank
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978475/
https://www.ncbi.nlm.nih.gov/pubmed/27504952
http://dx.doi.org/10.1371/journal.pone.0159924
work_keys_str_mv AT kliemanndimasalexandre geneticbarriertodirectactingantiviralsinhcvsequencesdepositedintheeuropeandatabank
AT tovocristianevalle geneticbarriertodirectactingantiviralsinhcvsequencesdepositedintheeuropeandatabank
AT gorinidaveigaanabeatriz geneticbarriertodirectactingantiviralsinhcvsequencesdepositedintheeuropeandatabank
AT machadoandreluiz geneticbarriertodirectactingantiviralsinhcvsequencesdepositedintheeuropeandatabank
AT westjohn geneticbarriertodirectactingantiviralsinhcvsequencesdepositedintheeuropeandatabank